Answers are grounded in this paper and cite their sources.
Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate-severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: